I wonder what we can discern from the fact that the first cohort data is being presented at two sessions in the upcoming Nov21 SNO conference.
On the first cohort data... would they really submit an abstract to simply say 'OK everyone, it's safe ... but no antitumoral activity evidenced'... is that really worth an abstract at the SNO (keep in mind the SNO would have had a sneak peak at what CHM wanted to present)? I'm guessing it was noteworthy enough that it demanded a slot...
On the second abstract on insights on how CLTX recognises GBM cells... for them to have anything insightful to present here, there would have had to have been some antitumoral activity at the lowest dose. Whether it be that some patients with certain biomarkers responded better than others, you would need to have some activity to contrast against a non/weak responder (which is the expected outcome at the lowest dose).
CHM Price at posting:
29.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)